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Abstract The tolerability of 57 non-smoking asthma patients inhaling salbutamol as needed (ATS,18--60 years, 60%
rFEV1r100%,PD15FEV1o0.4mghistamine) to fibreoptic bronchoscopy (FOB) andendobronchialbiopsywas studied.
The FOBwas done in local Lignocaine anaesthesia, and from five to eight biopsy specimenswere taken fromthe bron-
chial mucosa of the right lung. The tolerability was measured as cough/bronchospasm during the procedure (from
0 = normal to 3 = interrupted procedure), success of the procedure, anduntoward occurrences.Twenty-seven of the 57
patients (48%) had no cough or bronchospasm during the FOB (score 0). Few coughs of no importance (score1) were
documented in 23 patients (40%). Seven patients (12%) had cough and/or bronchospasminterfering with the FOBpro-
cedure (score 2).The FOB procedure was not interrupted because of cough and/or bronchospasm (score 3) in any pa-
tient. Scores of cough and/or bronchospasm diminished progressively with the increase of PD15FEV1 histamine. The
success ofthe procedurewas100%.Twopatientshaduntowardmedicaloccurrencesrequiringadditionalrescuemedica-
tion (3.5%). In conclusion, we found that hyperreactivity predicts cough and/or bronchospasm during the FOB.Cough
and/or bronchospasm are frequently observed during the bronchial procedure, but they are mild and of minor clinical
importance.Aninvestigationalendobronchialprocedure canbe successfullyperformedinmildlyormoderatelyobstruc-
tive asthmatic patients, even in caseswith severe bronchialhyperreactivity.r2002 Elsevier Science Ltd
doi:10.1053/rmed.2002.1304, available online athttp://www.idealibrary.comon
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Since the introduction of investigational endobronchial
biopsy via ¢breoptic bronchoscopy (FOB) in1977, no ser-
ious adverse events have been reported in asthmatic pa-
tients (1). Laryngospasm and bleeding appear in fewer
than 1/1000 patients (2). Half of the patients may have a
fall in FEV1, but only 15% of the subjects report breath-
lessness (2). The clinical signi¢cance of the changes of
thepulmonary function in connectionwith the FOBpro-
cedure is di⁄cult to assess. Bronchial obstruction and
hypoxaemia havebeenreported in rare cases and are as-
sumed to be more frequent in severely obstructive and/
or hyperreactive patients (3).The impact of bronchial hy-
perreactivity on the tolerability of investigative FOB has
not been studied. In a study with10 mild asthmatics, the
investigators calculated that approximately 60 patientsReceived19 December 2001, accepted in revised form10 January 2002.
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rate for bronchospasmwith a power of 80% (4).
The aim of the present study was to investigate the
tolerability of FOB and endobronchial biopsy among




The patients included to this analysis participated in a
randomized double-blind study comparing the e¡ects of
long-actingbeta2-receptor antagonist, disodiumcromo-
glycate and inhaled corticosteroid. All patients entering
the study underwent FOB before the treatment period.
Non-smoking18^60-year-old asthmatic patients [ATS
criteria (5)] were recruited. Patients included to the
study had an FEV1from 60 to100% of predicted value (6)
and a moderate or severe bronchial hyperreactivity
[provocative dose of histamine inducing a fall of 15% in
the forced expiratory volume of1s (PD15FEV1) less than
FIG. 1. Distribution of scores 0^2 cough/bronchospasm in
moderately (PD15FEV1less than 0.4mg) and severelyhyperreac-
tive (PD15FEV1less than 0.1mg) asthma patients.
BRONCHOSCOPYANDENDOBRONCHIALBIOPSYINASTHAMAPATIENTS 4670.4 and 0.1mg, respectively (7)]. The only medication
used before the FOB was inhaled short-acting beta2-
agonist when needed.
Procedures
The international consensus for the investigational FOB
was applied (3,8). Premedication was 30mg oxazepam
perorally, 0.5mg atropine intramuscularly, and inhaled
salbutamol 0.2mg. Lignocaine was given as local anaes-
thesia by inhalation andbypharyngeal and transbroncho-
scopic application up to a maximum dose of 500mg.The
bronchoscope (Olympus XT30,Tokyo, Japan) was intro-
ducedorally into the rightmainbronchus.The specimens
were taken with a cupped forceps from the mucosa of
the right upper lobe bronchus, the openings of the mid-
dle lobe bronchus and one of the basal bronchi of the
lower lobe.
The patients were followed up for 4h Adverse events
were recorded and gag re£ex examined by a drinking
test. Long-term adverse events were documented up to
2 weeks after the FOB.
Outcomemeasures of tolerability
Cough and/or bronchospasm: Cough and bronchospasm
during the FOB procedure were graded 0^3. Score 0
stood for no changes from the normal situation, 1 for
few coughs of no importance, 2 for cough and bronchos-
pasm interfering with FOB procedure, and 3 for FOB in-
terrupted because of cough and bronchospasm.
Adverse events: All untoward medical occurrences ex-
perienced by the patient were recorded as adverse
events (short-term during the 4-h polyclinical follow-up
after the FOB and long-term during the following 2
weeks).
Statisticalmethods:TheT-testwas used to compare the
di¡erence in the scores of cough/bronchospasm at the
di¡erent levels of bronchial hyperreactivity. The con¢-
dence interval for the occurrence of adverse events was
estimated.
RESULTS
Fifty-seven consecutive patients entering the study
were analysed. All patients completed the FOB proce-
dure with the number of specimens ranging from ¢ve
to eight.
Cough and/or bronchospasm
Twenty-seven of the 57 patients (48%) had no cough or
bronchospasm during the FOB (score 0). Few coughs of
no importance (score1) were documented in 23 patients
(40%). Seven patients (12%) had cough and/or bronchos-pasm interfering with the FOB procedure (score 2).The
FOB procedure was not interrupted because of cough
and/or bronchospasm (score 3) in any patient. Score 2
was foundmainly among severely hyperreactive patients
(PD15FEV1 histamine less than 0.1mg). The scores of
cough and/or bronchospasm diminished progressively
with the increase of PD15FEV1histamine.The di¡erence
between patients with cough/bronchospasm (scores 1
and 2) andwithout (score 0) (Fig1)was statistically signif-
icant (p=0.02).
Adverse events
Four of the 57 patients (7.0%,95% con¢dence interval 3^
17%) had a short-term adverse eventdocumented on the
FOB visit.One patient with PD15FEV1 histamine 0.14mg
had slight throat irritation and cough. Another patient
with PD15FEV1histamine 0.02mghadmildhaemopthysis.
These symptoms resolved spontaneously. Two patients
had dyspnoea. One of them had PD15FEV1 histamine
0.03mg and the other had PD15FEV1 histamine 0.24mg.
Both patients quickly responded to salbutamol taken as
rescue medication. The follow-up time of the patients
was not prolonged because of any of these adverse
events.
The most common long-term adverse events during
the 2-week (post-bronchoscopy days 0^13) period fol-
lowing the FOB were headache (nine episodes), respira-
tory infection (four episodes), and increase in asthma
symptoms (three episodes), which responded to rescue
medication (inhaled salbutamol).
DISCUSSION
Fifty-seven hyperreactive asthma patients completed
the investigative FOB protocol with endobronchial
468 RESPIRATORYMEDICINEbiopsy without complications interfering with the pro-
cedure. Severe cough and/or bronchospasm or severe
short-term adverse events were not detected. Bronchial
hyperreactivity predicted cough and/or bronchospasm
during the FOB.
Thepresent study suggests that adverse events imme-
diately related to the FOB procedure are present with
a frequency of 3^17%. In this study they were mild
and resolved rapidly without prolonging the stay at
hospital. During the 2-week follow-up, only three
patients reported increase in asthma symptoms
which responded to rescue medication (inhaled salbuta-
mol). The most frequent adverse events during the
two-week follow-up in our study, i.e. headache and
respiratory infection did not have any ¢xed relation-
ship to the bronchial procedure. Our ¢nding is thus
comparable with that of Humbert et al. who reported
no delayed e¡ects on asthma control up to 2weeks after
FOB (9).
The present results with 57 patients as well as some
previous studies suggest that the investigative FOB can
be safely performed in mildly or moderately obstructive
asthma patients (9,10). This study also shows that FOB
with endobronchial biopsy is well tolerated in pre-medi-
cated asthmatics with a mild-to-moderate obstruction,
even in cases of severe bronchial hyperreactivity. Pre-
and rescuemedicationwere su⁄cient to treat all clinical
consequences of the investigative FOB and endobron-
chial biopsy in the present study. Asthmatics with severe
obstruction and extreme bronchial hyperreactivity are
not recommended to be taken into studies including in-
vestigative FOB (3).
In conclusion, we found that hyperreactivity predicts
cough and/or bronchospasm during the FOB. Cough
and/or bronchospasm are frequently observed during
the bronchial procedure, but they are mild and of minor
clinical importance. An investigational bronchial proce-
dure can be successfully performed in mildly or moder-
ately obstructive asthmatic patients, even in cases with
severe bronchial hyperreactivity.Acknowledgements
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